Open company graph database — free web & API
Login

Sohiken Holdings Co., Ltd.

株式会社総医研ホールディングス
Ticker
Listed market
TYO
Country
Japan
Employees (non-consolidated)
11
Related companies
8
§01

Basic information

BASIC
Head office
13th Floor, Senri Life Science Center, 1-4-2 Shin-Senri Higashimachi, Toyonaka City, Osaka 560-0082, Japan
Chief executive
Masao Tsunoda
Capital
1,836,000,000 JPY (18 100 millionJPY)
Employees (non-consolidated)
11 people
Employees (consolidated)
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

14
Evaluation testing businessBiomarker development businessHealthcare support businessFatigue quantification technology using human herpesvirusCommercialization of medical scientific research achievementsHealth supplement businessFunctional material research and salesHigh-performance cosmetics salesGene therapy vector research and developmentPharmaceutical development supportFood and cosmetic development supportHealthcare servicesHealth supplement salesFunctional material research and development
§04

Related companies

8 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
General Incorporated Association Specialist Medical Doctor Healthcare Network
Group Alliance
NRL Pharma Inc.
Group Alliance
Evidence Lab Inc.
Group Alliance
BB Laboratories Inc.
Group Alliance
Japan Preventive Medicine Co., Ltd.
Group Subsidiary
Willus Medical Science Institute Inc.
Group
Virus Medical Science Institute
Group Subsidiary
General Medical Science Research Institute Inc.
Group Subsidiary
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

40 EVENTS

July 1994: Established Sohiken Medical Science Laboratory, a limited company in Sakai City, Osaka Prefecture, with capital of 3,000,000 yen, aiming to develop biomarkers and bioevaluation systems useful for clinical drug development.Sources

Our group, in July of the 6th year of Heisei (1994), established by our director Osamu Kajimoto, develops biomarkers and bioevaluation systems using them to establish new pharmaceuticals and functional foods.Sources

Established Sogo Medical Science Research Institute Ltd. in Sakai City, Osaka Prefecture, with capital of 3 million yen, for the development of biomarkers and bioevaluation systems useful for clinical drug development.Sources

In July of Heisei 6 (1994), our director Osamu Kajimoto established a new pharmaceutical and functional product development system through biomarker development and bio-evaluation system establishment.Sources

June 1996: Moved headquarters to Chuo Ward, Osaka City.Sources

Relocated headquarters to Chuo-ku, Osaka. Established Japan Clinical System Inc. (now a consolidated subsidiary) for the sale of functional foods and planning/sales of medical devices.Sources

April 2001: Moved headquarters to Toyonaka City, Osaka Prefecture.Sources

Relocated headquarters to Toyonaka City, Osaka Prefecture.Sources

December 2001: Changed organization to Sohiken Co., Ltd.Sources

Organizational change to Sogo Medical Science Research Institute Inc.Sources

May 2002: Started business alliance with Sohiken Clinic.Sources

Started business alliance with Sogo Clinic.Sources

June 2003: Signed a research contract with Osaka City University for the development of food and drug products using new biomarkers and their functional analysis for fatigue and related conditions.Sources

Signed a research consignment contract with Osaka City University for the development of fatigue-related food drugs using new biomarkers and their functional analysis.Sources

July 2003: Opened Tokyo Branch in Minato-ku, Tokyo.Sources

Opened a Tokyo branch in Minato Ward, Tokyo.Sources

October 2003: Started fatigue quantification and anti-fatigue food drug development project.Sources

Started a project for quantification of fatigue and development of anti-fatigue food medicines.Sources

December 2003: Listed on the Mothers section of the Tokyo Stock Exchange.Sources

Listed shares on the Mothers section of the Tokyo Stock Exchange.Sources

December 2005: Established Virus Medical Science Research Institute Inc. (now a non-consolidated subsidiary) to commercialize fatigue biomarkers using viruses.Sources

Established Virus Medical Science Research Institute Inc. (currently a non-consolidated subsidiary) for the commercialization of fatigue biomarkers using viruses.Sources

January 2006: Established Evidence Lab Inc. (now a consolidated subsidiary) in joint venture with Hakuhodo Inc. for post-marketing surveys and marketing research of specified health foods, etc., through a website that disseminates information on specific health foods.Sources

Established Evidence Lab Inc. (currently a consolidated subsidiary) in joint venture with Hakuhodo Inc. for the purpose of conducting post-marketing surveys and marketing research of health foods, etc., through a website that disseminates information about specified health foods.Sources

July 2006: Acquired B.B. Laboratories Inc. and two other companies (now consolidated subsidiaries) to expand into the cosmetics business.Sources

Acquired B.B. Laboratories Inc. and two other companies (currently consolidated subsidiaries) to expand into the cosmetics business.Sources

January 2007: Transitioned to a holding company structure to improve group management efficiency and strengthen corporate governance. Established Sogo Medical Science Research Institute Inc. as a new company through a spin-off of business divisions, and changed the company name to Sogo Kenko Holdings Inc.Sources

Transitioned to a holding company structure to improve group management efficiency and strengthen corporate governance. Established a new business division as a spin-off, and founded Sogo Medical Science Research Institute Inc. (currently a consolidated subsidiary) as a new company, with the company becoming a holding company and changing its trade name to Sogo Medical Science Research Institute Inc.Sources

May 2007: Changed the trade name of Japan Clinical System Inc. to Japan Preventive Medicine Inc. to commercialize functional foods for medical institutions, and subscribed to the issuance of new shares through a shareholder allocation, making it a consolidated subsidiary.Sources

Changed the trade name of Japan Clinical System Inc. to Japan Preventive Medicine Inc. to commercialize functional foods and other products for medical institutions, and subscribed for new shares issued through a shareholder allotment, making it a consolidated subsidiary.Sources

February 2008: Relocated Tokyo Branch to Chiyoda-ku, Tokyo.Sources

Relocated the Tokyo branch to Chiyoda Ward, Tokyo.Sources

May 2015: Signed a business and capital alliance agreement with Chinese cosmetics company Beautyplus Holdings Hongkong Limited to build a cooperative relationship for cosmetics sales in the Chinese market.Sources

Signed a business alliance and capital alliance agreement with Chinese cosmetics company Beautyplus Holdings Hongkong Limited to build a cooperative relationship for cosmetics sales in the Chinese market.Sources

June 2017: Made NRL Pharma Inc., which develops and sells functional ingredients centered on lactoferrin, a consolidated subsidiary.Sources

Made NRL Pharma Inc., which develops and sells functional ingredients centered on lactoferrin, a consolidated subsidiary.Sources

February 2019: Signed a capital and business alliance agreement with Chinese distribution company Hangzhou Golong Holding Co., Ltd. to build a partnership for cosmetics and health supplement sales in China.Sources

Signed a capital and business alliance agreement with Chinese distribution company Hangzhou Golong Holding Co., Ltd. to build a partnership for cosmetics sales and health supplement sales in the Chinese market.Sources

April 2022: Transitioned from the Tokyo Stock Exchange Mothers to the Growth Market due to a review of market classification.Sources

Moved from the Tokyo Stock Exchange Mothers market to the Growth market due to a review of market classification.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information4120901026508
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社総医研ホールディングス
Trade name (kana)
ソウイケンホールディングス
Name in English
Corporation type
301
Address
〒560-0082 大阪府豊中市新千里東町1丁目4番2号
Postal code
5600082
Prefecture code
27
City code
203
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-07-06
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
4185270
METI gBizINFO4120901026508
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
4120901026508
Trade name
株式会社総医研ホールディングス
Trade name (kana)
ソウイケンホールディングス
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
大阪府豊中市新千里東町1丁目4番2号
Postal code
5600082
Prefecture
大阪府
Prefecture code
27
City or district
豊中市
City code
203
Street address
新千里東町1丁目4番2号
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
代表取締役社長  角田 真佐夫
Capital
1836587000
Employees
7
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-07-06
Key information
4120901026508
§09

Sources & updates

SOURCES
↑